Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04338269 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 522
- Enrollment target
NCT04338269 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 522 participants.
The verdict
NCT04338269, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 522 participants
- Enrollment target
Study Summary
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune Checkpoint Inhibitor (ICI) treatment in the metastatic setting.
Interventions
- DRUG Atezolizumab
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 522 participants |
| Start Date | 2020-07-28 |
| Est. Completion | 2025-03-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04338269
The ClinicalTrials.gov registry entry for NCT04338269 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 522 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT04338269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04338269 about?
NCT04338269 is a clinical study titled "A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment". This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced rad...
What is the current status of trial NCT04338269?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 522 participants. The study started on 2020-07-28. Estimated completion is 2025-03-24.
What interventions are being tested in trial NCT04338269?
The interventions under investigation include: Atezolizumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04338269?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.